Introduction
A previously healthy 4-year, 10-month old boy (18 kg) was seen by his pediatrician for a fever to 101°F and an overnight "barky cough." He received an oral dose of dexamethasone and was discharged home. Later that afternoon, he developed increased respiratory distress and was evaluated in an outside hospital. He received a 20-mL/kg normal saline intravenous (IV) bolus, a racemic epinephrine nebulization, and IV dexamethasone. Due to concerns of impending respiratory failure, he was transferred to a higher level of care facility.
Upon arrival of the transport team, he was breathing at a rate of 60 breaths/min while receiving 15 L/min of oxygen via a nonrebreathing facemask. He was restless, but warm and well perfused with strong pulses. His breathing increased during transport and he was placed on continuous positive airway pressure at 10 cm H 2 O. Despite maximal medical interventions, he required immediate intubation and mechanical ventilation due to hypoxemic respiratory failure when he arrived to the pediatric intensive care unit (PICU).
Later in the evening, he was found to have anisocoria and was given hypertonic (3%) saline. An emergent head computed tomography scan (CT scan) was normal. Approximately 17 hours after admission, an arterial blood gas demonstrated a pH of 7.19, PaCO 2 of 50 mm Hg, PaO 2 of 85 mm Hg, and a base deficit of À9.1. He was receiving conventional mechanical ventilation in the pressure-regulated volume control modality with a tidal volume of 6 mL/kg, positive end-expiratory pressure of 14 cm H 2 O, rate of 30, and FiO 2 of 70% while in the prone position. His peak inspiratory pressure (PIP) was 33 cm H 2 O. Due to hemodynamic instability, patient continued to receive large crystalloid and colloid volume resuscitation. His net fluid balance at this point was close to 2.7 positive. His chest X-ray revealed patchy peripheral and bilateral lower lobe opacities with left pleural effusion (►Fig. 1A). Given his worsening metabolic acidosis, increasing pulmonary edema, and elevated central venous pressure, an echocardiogram was ordered to assess his cardiac function. He was noted to have good systolic function but diastolic dysfunction. Milrinone was initiated at a continuous IV rate of 0.3 µg/kg/h. A complete blood count demonstrated a white blood cell count of 660 cells/mm 3 (64% lymphocytes, 24% segmented neutrophils, 188 absolute neutrophil count, and 422 absolute lymphocyte count). Polymerase chain reaction analysis for respiratory syncytial virus from a nasopharyngeal secretion sample was positive. His throat and blood cultures grew group A Streptococcus (GAS) bacteria approximately 19 hours after admission. He was treated empirically with cefotaxime and clindamycin. He also received IV immunoglobulin G (IVIG) and plasmapheresis.
The patient continued to require volume resuscitation and was treated with escalating doses of continuous vasopressor infusions including dopamine 20 µg/kg/min, epinephrine 0.2 µg/kg/min, norepinephrine 0.2 µg/kg/min, and milrinone 0.5 µg/kg/min. Vancomycin was added to his antibiotic regimen. A repeat echocardiogram revealed diminished left ventricular systolic function. Due to signs of inadequate oxygen delivery and hypoxemia, inhaled nitric oxide was introduced at 20 ppm. During this time, he developed a right-sided tension pneumothorax that was managed with a right-sided chest tube (►Fig. 1B, C). Despite these measures, his metabolic acidosis persisted and his lungs remained poorly compliant with PIPs ranging from 45 to 50 cm H 2 O. He went into cardiac arrest twice requiring cardiopulmonary resuscitation for approximately 2 and 15 minutes, respectively. His serum lactate levels continued to rise (up to 9 mmol/L) despite maximal medical support, thus the decision was made to electively place him on peripheral venoarterial extracorporeal membrane oxygenation (VA ECMO). He was cannulated via his right internal jugular vein with a 22-French catheter and his right carotid artery with a 16-French catheter. Shortly after peripheral VA ECMO initiation, his heart went into asystole and his lung fields appeared to have near total opacification (►Fig. 2B). He developed anasarca and exhibited intermittent anisocoria. Over the following 22 hours, his venous return progressively worsened despite aggressive fluid administration and inotropic support. In addition, he became anuric and developed abdominal compartment syndrome, and at this point, his net fluid balance was more than 5 L positive.
Thus, his peripheral VA ECMO support was converted to open chest central VA ECMO support via a median sternotomy with the addition of a 24-French venous catheter to his right atrium. In addition, his left atrium was vented with a 13-French catheter. The 16-French arterial catheter was left in the right carotid artery. His heart was observed to be markedly enlarged. Significant bilateral pleural effusions were drained directly via his sternotomy incision. Two chest tubes and a mediastinal drain were placed and the sternotomy was covered with a Silastic membrane. A Tenckhoff peritoneal catheter was also placed after a significant amount of ascites was surgically drained. After the addition of transthoracic cannulas, he had rapid and substantial improvement in his ECMO flows increasing from 67 to 88 mL/kg/min in peripheral ECMO to 150 to 200 mL/kg/min after central cannulation (patient's dry weight was 18 kg at admission). His lactic acidosis improved as well. Over the following week, his cardiac function improved. On day 8 of VA ECMO, his transthoracic cannulas were removed, and he was transitioned back to full support via his right neck vessels (peripheral VA ECMO). Patient received continuous renal replacement therapy while on central ECMO, his kidney function started to improve gradually, and he required slow continuous ultrafiltration for fluid removal intermittently through his course.
Approximately 1 month into his VA ECMO support, he developed septic shock secondary to Hemophilus influenzae that was isolated from his blood, respiratory secretions, and pericardial fluid. He experienced significant bleeding from his mediastinum. Efforts were made to minimize his anticoagulation by maintaining antifactor Xa levels in the range of 0.3 to 0.4 while normalizing his prothrombin time and platelet levels (goal of > 100,000/µL). His antibiotic regiment of cefepime and meropenem was simplified to ceftriaxone to target GAS and H. influenzae.
On day 37 of VA ECMO, mediastinal debridement was performed due to concerns that he had developed mediastinitis. At this time, he was found to have a bronchopleural fistula originating from his right lung. The area was packed with a kaolin impregnated sterile gauze (QuickClot). To limit the positive pressure reaching his right lung and the fistula to heal, the otolaryngology service performed bronchoscopy and placed his endotracheal tube in the left main bronchus. After 2 days, mediastinal re-exploration was performed and the kaolin impregnated sterile gauze was removed with no resulting air leak. After 7 days, the endotracheal tube was pulled back to its typical position above the carina. His mediastinum was gradually closed over the course of several weeks.
Multiple efforts to wean him off of VA ECMO support and transitioning to VV ECMO were unsuccessful because of severe respiratory acidosis even and the liable hemodynamic status. On day 59 of VA ECMO support, he was transitioned to pumpless extracorporeal CO 2 removal (ECCO 2 R) by placing a 14-French cannula in both his left femoral artery and left femoral vein. His peripheral (right neck) ECMO cannulas were removed at that time. Over a few weeks, his ECCO 2 R support was gradually weaned. He was decannulated from ECCO 2 R on day 75 of total extracorporeal support.
While on ECMO, patient was on Rotaflow ECMO system. While he was on VA ECMO, flow range was 2 to 3.5 L/min, sweep varied greatly depending on age of oxygenator, his sweep range between 2.5 and 8 L/min with higher sweep resulting in frequent oxygenator changes for clotting and poor gases. FiO 2 range between 50 and 100% for majority of his run up until ECCO 2 R.
While on ECCO 2 R, patient was on Rotaflow ECMO system. He started on pediatric Quadrox oxygenator, but was changed to adult Quadrox within 12 hours to achieve higher flow rate. He remained on adult Quadrox for the remainder of his ECCO 2 R. ECCO 2 R flow ranged between 0.4 and 0.5 L/min. Sweep rate ranged between 2 and 3 L/min at 21% FiO 2 .
Heparin was used for anticoagulation with activated clotting time (ACT) goal of 160 to 180. Due to bleeding complications from chest, ACT range was lowered to 140 to 160 for majority of treatment. Heparin infusion was often at variable doses between 40 and 50 units/kg/h. After 4.5 months of hospitalization, tracheostomy and gastrostomy tubes were placed. On day 167 of hospitalization, efforts to sprint him off of the ventilator to a tracheostomy collar began. The patient was discharged from the hospital requiring night time ventilation through the tracheostomy tube. Overall, he spent 229 days in the hospital, 152 days in the PICU and 77 days in the rehabilitation unit. At the time of his discharge, the only neurological deficit that he exhibited was poor fine motor skills in his hands for which he continued to receive physical therapy. He was discharged home on amlodipine for systemic hypertension, sildenafil for pulmonary hypertension, albuterol, and ipratropium.
Gradually, he was successfully weaned off of the ventilator and supplemental oxygen over a period of 6 months. He tolerated the capping of his tracheostomy tube throughout the day. He experienced shortness of breath while running, but he was able to engage in normal activity without any significant respiratory problems. Fourteen months after his original admission, spirometry revealed low vital capacity at 59% (0.84 L) of predicted value for his age; nose clips and Microfoam tape around the tracheostomy were used to mini-mize air leak during testing. These observations were consistent with restrictive lung disease. A polysomnogram was performed with the tracheostomy tube capped and demonstrated normal oxygenation and ventilation.
A follow-up chest radiograph revealed minor residual atelectasis in the left lower lobe with small bilateral chronic pleural effusions (►Fig. 2D). A chest CT scan demonstrated traction bronchiectasis, atelectasis, and consolidation of bilateral lower lung lobes greater on the left compared with the right (►Fig. 3). Serial echocardiograms did not show any evidence of pulmonary artery hypertension; therefore, sildenafil was successfully weaned off.
Discussion
Streptococcus pyogenes is a β-hemolytic bacterium that is also known as GAS. Invasive GAS accounts for 8,950 to 11,500 cases and 1,050 to 1,850 deaths each year in the United States. 1 The rates of disease are highest among children who are younger than 1 year of age and persons older than 65 years of age. 1 GAS is responsible for a spectrum of illnesses in children, ranging from pharyngitis to fatal invasive disease, 2,3 and it is an emerging cause of severe sepsis in children. 4 In one case series from Melbourne over a 3-year period, 12 cases of invasive group A streptococcal infection were admitted to the PICU. 4 The most common clinical presentations were pneumonia, bacteremia with no septic focus, and septic arthritis. Fever and hypotension were common signs, but a rash was infrequent. The typical patient had multiorgan dysfunction including some combination of acute respiratory distress syndrome (ARDS), renal failure, liver dysfunction, and coagulopathy. 4 Half of the patients required ECMO support ranging from 4 to 35 days though there was no mention of which type of ECMO support, peripheral or central, was needed. 4 Initial management of invasive GAS infections is centered on early antimicrobial therapy, ensuring adequate cardiac output and supporting failing organs. 2 A two-pronged parenteral antimicrobial therapy strategy is recommended utilizing a bactericidal agent (β-lactamase-resistant antimicrobial) and a protein synthesis inhibiting agent (e.g., clindamycin) to diminish production of virulence factors. 5 IVIG should be considered for those refractory to escalating hemodynamic support and meeting criteria for streptococcal toxic shock syndrome. 5, 6 The use of ECMO is part of the clinical practice parameters guidelines for hemodynamic support of pediatric and neonatal septic shock. 7 The procedure is a form of cardiopulmonary bypass, modified for longer term support. The patient's venous blood is emptied from the body via a large bore cannula, and then, it is directed through a membrane oxygenator where carbon dioxide is removed and oxygen is added before being returned into the venous or arterial circulation. 8 The typical insertion sites of the cannulas for peripheral ECMO include the large vessels of the neck and/or groin. In central ECMO, the venous cannula is placed in the inferior vena cava or right atrium (in a transthoracic approach), while the arterial cannula is inserted into the ascending aorta by way of a median sternotomy. In general, patients with isolated respiratory or cardiac failure are successfully supported using ECMO flows that can be achieved using peripheral ECMO. Physical properties of the length and diameter of the catheters and the size of the vascular bed being drained play a role in the limitation of ECMO flow. 9 Our patient benefited from the higher flows achieved with central ECMO as well as decompressing the tamponade caused by extensive pleural edema and effusion from disease severity and fluid resuscitation.
We are certainly not the first institution to use central ECMO [10] [11] [12] [13] for support of refractory septic shock, in either children [11] [12] [13] [14] or adults. 15 MacLaren et al published a case series of children, many with overwhelming meningococcemia, who had good outcomes utilizing central ECMO support in the setting of septic shock by aiming to achieve "supernormal" ECMO flow to improve tissue bed perfusion, overcome vasomotor paralysis, and resolve lactic acidosis. 14 While the successful use of central ECMO in septic shock has been reported, its use in children still seems to be merely a consideration rather than an expectation. At the time of this patient's presentation, we had extensive experience using peripheral ECMO for support of septic shock, but often with disappointing results due to the inability to achieve the desired supernormal ECMO flow. Our institution had extensive experience with transthoracic ECMO support for cardiac failure, often postoperatively. Given these experiences and the willingness of our cardiac surgical team to attempt to support this patient with central ECMO, making the imaginative leap to put into practice the lessons taught by our Australian colleagues was a relatively easy one. In the largest Australian series reported using central ECMO support for refractory septic shock, survival was statistically associated with maximal ECMO flow achieved with survivors able to reach ECMO flows of 158 versus 111 mL/kg/min for nonsurvivors. 14 For our patient, ECMO flow increased from 67 to 88 mL/kg/min in peripheral ECMO to 150 to 200 mL/kg/min after central cannulation. It should be noted that these ECMO flows are approximately 50% higher than those typically recommended for venoarterial support of either primary respiratory failure or primary cardiac failure.
The use of ECCO 2 R to "bridge" our patient off VA ECMO support was a first for our institution, though use of ECCO 2 R for support of respiratory failure associated with severe hypercapnia is certainly not novel, particularly in adult critical care medicine. ECCO 2 R, also discussed in the literature as "lowflow ECMO," may be performed in a venovenous or an arteriovenous manner, analogous to continuous renal replacement therapy. 16 It allows use of ultraprotective ventilation strategies with very small tidal volumes and transalveolar pressures. 16 Scattered case reports of the use of ECCO 2 R in pediatric ARDS (PARDS) have been in existence since the early 1990s, 17 but given that the primary derangement in PARDS tends to be hypoxemia rather than hypercapnia, [18] [19] [20] most pediatric respiratory ECMO support has traditionally used "high-flow" ECMO, either venoarterial or venovenous. 8, 10 Our patient's ARDS caused hypercapnia rather than hypoxemia off ECMO support, beside the fact that the ECCO 2 requires less anticoagulation and are associated with less complication; we were encouraged to use it instead of VV ECMO as a bridge to wean our patient off of ECMO support.
Conclusion
Group A streptococcal infection can present with a wide range of clinical symptoms from fever and sore throat to severe lifethreatening sepsis. Our patient's symptoms evolved acutely and he remained hemodynamically unstable despite aggressive medical management. Peripheral ECMO cannulation initially stabilized his condition, but then his hemodynamics deteriorated with insufficient flow to meet his metabolic needs. Central ECMO along with drainage of his pleural effusions and intraabdominal ascites significantly improved his blood flow from 67 to 88 to 150 to 200 mL/kg/min. After approximately 2 months on ECMO, he was transitioned to ECCO 2 R due to refractory respiratory acidosis. He was completely decannulated approximately 2 weeks later with good neurological recovery. This experience suggests that consideration should be given for the use of central ECMO in pediatric patients who remain hemodynamically insufficient/ unstable due to sepsis while on maximally optimized peripheral ECMO support. Furthermore, ECCO 2 R is a reasonable supportive option in children who exhibit persistent respiratory acidosis while recovering from ARDS.
